US 11,773,130 B2
3′ protected nucleotides
Frank Bergmann, Iffeldorf (DE); Peter Crisalli, Mountain View, CA (US); Dieter Heindl, Munich (DE); Omid Khakshoor, Lathrop, CA (US); and Meng Taing, Hayward, CA (US)
Assigned to Roche Sequencing Solutions, Inc., Pleasanton, CA (US)
Filed by Roche Sequencing Solutions, Inc., Pleasanton, CA (US)
Filed on Jul. 6, 2022, as Appl. No. 17/858,099.
Application 17/858,099 is a continuation of application No. 17/416,186, granted, now 11,440,933, previously published as PCT/US2019/066670, filed on Dec. 16, 2019.
Claims priority of provisional application 62/781,638, filed on Dec. 19, 2018.
Prior Publication US 2022/0348604 A1, Nov. 3, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C07H 19/06 (2006.01); C07H 19/048 (2006.01)
CPC C07H 19/06 (2013.01) [C07H 19/048 (2013.01)] 23 Claims
 
1. A nucleotide or a salt thereof of Formula (VA):

OG Complex Work Unit Chemistry
wherein
X is a nucleobase or a tagged nucleobase;
Y is —O—P(O)(OH)—[O—P(O)(OH)]z—OH or —O—P(O)(OH)—[O—P(O)(OH)]z—O-oligonucleotide, where z is 0 or an integer ranging from 1 to 5;
R1 is a bond, a —CH2—, —C(O)—O—, —C(O)—NRa—, or —C(O)—Rx—;
R2 and R3 are each independently H, a saturated or unsaturated C1-C6 alkyl group, a C5-C6 aryl or heteroaryl group, a halogen, —[(C(Ra)(Rb))p—O]q (Ra), —C(O)—ORa, —C(O)—N(Ra)(Rb), —(C(Ra)(Rb))n—N+C−, —CN, or —NO2;
R4 is a bond, a substituted or unsubstituted 5- to 7-membered aryl group, —CH═CH—, a substituted or unsubstituted 5- or 6-membered heterocycloalkyl group, or —O—C(O)-aryl-;
where Z1 and Z2 are independently H or a C1-C4 alkyl group;
Ra and Rb are each independently H or a saturated C1-C6 alkyl group;
Rx is a substituted or unsubstituted 5- or 6-membered aromatic group or heteroaromatic group;
n is 0 or an integer ranging from 1 to 3; and
p and q are each independently zero or an integer ranging from 1 to 3.